News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Noven Pharmaceuticals Inc. (NOVN) Submits New Drug Application for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms



8/29/2012 9:43:33 AM

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.

Read at BioSpace.com


comments powered by Disqus
   
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES